Telomir Pharmaceuticals, Inc.
TELO
$1.22
$0.032.52%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -79.06% | -36.48% | -19.02% | 20.09% | 318.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -62.35% | -25.30% | -14.33% | 7.96% | 198.14% |
| Operating Income | 62.35% | 25.30% | 14.33% | -7.96% | -198.14% |
| Income Before Tax | 63.59% | 26.31% | 37.24% | 51.13% | 13.89% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 63.59% | 26.31% | 37.24% | 51.13% | 13.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 63.59% | 26.31% | 37.24% | 51.13% | 13.89% |
| EBIT | 62.35% | 25.30% | 14.33% | -7.96% | -198.14% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -67.98% | 30.54% | 41.19% | 54.45% | 20.45% |
| Normalized Basic EPS | 71.83% | 30.53% | 41.17% | 31.30% | -33.83% |
| EPS Diluted | -67.98% | 30.54% | 41.19% | 54.45% | 20.45% |
| Normalized Diluted EPS | 71.83% | 30.53% | 41.17% | 31.30% | -33.83% |
| Average Basic Shares Outstanding | 35.34% | 9.81% | 7.73% | 6.79% | 6.70% |
| Average Diluted Shares Outstanding | 35.34% | 9.81% | 7.73% | 6.79% | 6.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |